CVA21

Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Syngenic, Immune system, NSCLC, Congress, Non-small-cell lung carcinoma, Glioblastoma, RCC, RNA, Cancer, IND, Large-cell lung carcinoma, SCLC, Renal cell carcinoma, Squamous cell carcinoma, Patient, Melanoma, Burn, SVV, Annual report, EGFR, Workforce, Genome, Wilms' tumor, Senecavirus, Nature Communications, Security (finance), GEMM, Mouse, HCC, Hepatocellular carcinoma, IV, RNA transfection, CVA21, Immunotherapy, Investment, Safety, Vaccine, Pharmaceutical industry, PDX, LNP

As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.

Key Points: 
  • As part of this reprioritization, we are discontinuing the Phase 1 trial of ONCR-177 to focus our resources on ONCR-021.
  • Oncorus will present the results of the Phase 1 study of ONCR-177 in patients with advanced disease in conjunction with a scientific congress in 2023.
  • ONCR-021 is Oncorus lead candidate from its self-amplifying RNA platform intended to allow for intravenous (IV) administration.
  • At Oncorus, we are focused on driving innovation in RNA medicines by developing next-generation immunotherapies to stimulate the immune system and transform outcomes for cancer patients.

Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer

Retrieved on: 
Friday, October 7, 2022
SVV, U.S. Securities and Exchange Commission, RNA transfection, HSV, Renal cell carcinoma, Transgene, Therapy, Syngenic, SEC, Investor, IND, Virus, Neoplasm, Annual report, Patient, IV, Hepatocellular carcinoma, RNA, Security (finance), Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SCLC, Nasdaq, GEMM, Cancer, Private Securities Litigation Reform Act, Mouse, Immune system, Company, Large-cell lung carcinoma, Research, Safety, GLOBE, Melanoma, Nature Communications, CVA21, FDA, COVID-19, LNP, Risk, Vaccine, PDX, Senecavirus, Young LNP

The article describes the design and development of Oncorus synthetic RNA viruses for the systemic treatment of cancer.

Key Points: 
  • The article describes the design and development of Oncorus synthetic RNA viruses for the systemic treatment of cancer.
  • By encapsulating vRNA in LNPs, Oncorus was able to recapitulate oncolytic viral therapy in various tumor cells and avoid neutralizing antibodies.
  • The vRNA/LNP constructs were well tolerated and elicited tumor-specific in situ production of oncolytic virions, immune cell recruitment and tumor destruction.
  • Overall, synthetic RNA viruses were well tolerated after a single or multiple IV dose in mice and non-human primates.

Oncorus Presents Preclinical Data on ONCR-021 and ONCR-788 Supporting Selectively Self-Amplifying vRNA Immunotherapy Platform at AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
RCC, Private Securities Litigation Reform Act, PDX, Therapy, Degenerative disease, Investor, Orthornavirae, IND, AACR, Risk, Immunotherapy, Tropism, American Association, Neoplasm, Cancer, Mark (given name), RNA, U.S. Securities and Exchange Commission, NSCLC, Renal cell carcinoma, Food, Security (finance), Genome, Immune system, Association, American Association for Cancer Research, Safety, RNA transfection, Transgene, CDX, HSV, Nasdaq, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Melanoma, Myelocyte, SVV, Senecavirus, CVA21, Wilms' tumor, LNP, Annual report, FDA, Potyvirus, PD-L1, GEMM, Patient, Large-cell lung carcinoma, IV, Pharmaceutical industry, Vaccine

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced its presentation of preclinical data for both ONCR-021 and ONCR-788 in two e-posters at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana, supporting the company’s selectively self-amplifying viral RNA (vRNA) Immunotherapy Platform.

Key Points: 
  • The preclinical data presented on ONCR-021 and ONCR-788 at AACR are an important step forward for Oncorus novel approach of selectively self-amplifying vRNA immunotherapies formulated in lipid nanoparticles.
  • Oncorus vRNA Immunotherapy Platform encapsulates the genomes of RNA viruses known to kill cancer cells within an LNP, producing a living oncolytic and immunostimulatory viral infection in the tumor to destroy cancer cells and stimulate the immune system.
  • In preclinical studies, Oncorus IV-administered vRNA immunotherapies demonstrated efficacy in multiple tumor models, avoiding the challenges seen in previous studies incorporating IV administration of RNA-based oncology therapeutics.
  • Designed to deliver next-generation viral immunotherapy impact, our HSV Platform improves upon key characteristics of this therapeutic class to enhance systemic activity.